Anebulo Pharmaceuticals (ANEB) Appoints Kenneth Cundy as Chief Scientific Officer
- Stocks tumble after weak U.S. confidence data; oil gains
- Earnings Estimates are 'Likely Too Optimistic', Risk Not Fully Reflected - Goldman
- Pinterest (PINS) CEO Silbermann Is Stepping Down, Shares Gain 8%
- Apple's (AAPL) Runs into 5G Modem Development Issues, Will Continue to Use Qualcomm (QCOM) - Analyst
- Bank of America Clients are Selling This Rally
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB) today announced the appointment of Dr. Kenneth Cundy, Ph.D. as Chief Scientific Officer of the Company. Dr. Cundy is a highly respected scientist having innovated and developed multiple therapeutics throughout his career.
“I am thrilled to welcome Ken to the Anebulo team, his expertise in drug development comes at an opportune time for the Company as we advance ANEB-001 through human clinical trials for acute cannabinoid intoxication,” said Simon Allen, Chief Executive Officer of Anebulo. “Ken’s broad experience in drug discovery, preclinical and clinical development, and product approval spans more than 30 years with various companies and includes blockbuster drugs such as Gilead’s HIV drug tenofovir and the filing of more than 15 INDs and 6 NDAs.”
In addition to his extensive drug development experience, Dr. Cundy has a proven record of successful innovation, with 50 issued U.S. and over 100 international patents to his name. He also has extensive experience in interacting with partners, the FDA, and international regulatory agencies.
“I look forward to leading Anebulo’s research and development initiatives as we advance ANEB-001 into later stage clinical trials,” said Dr. Cundy. “I am particularly impressed by the compelling pharmacology of our lead program and the exciting data generated to date. Together, with the rest of the Anebulo team, we have the opportunity to deliver a groundbreaking therapy for ACI to treat this serious and rapidly growing unmet need.”
Prior to joining Anebulo, Dr. Cundy served as Chief Scientific Officer at CohBar, Inc., a publicly-traded biotechnology company developing therapeutics targeting chronic and age-related diseases, where he built and expanded a technology platform around novel analogs of regulatory peptides encoded in the mitochondrial genome, advanced their lead program from pre-clinical to successful clinical proof of concept for NASH and obesity, and secured these innovations with multiple issued patents. Before CohBar, Dr. Cundy was Chief Scientific Officer at XenoPort, Inc., a biopharmaceutical company focused on therapeutics for neurological disorders. He was coinventor of XenoPort’s approved drug Horizant®, and led efforts from discovery to development and approval for the treatment of postherpetic neuralgia and restless legs syndrome in the US and Japan. Previously, Dr. Cundy held various positions at Gilead Sciences, Inc. where he was a key contributor to the development of Gilead’s antiviral franchise, including blockbuster drugs such as Viread®, Hepsera®, Vistide®, and Tamifu®. He was coinventor of Gilead’s transformational blockbuster drug tenofovir disoproxil, approved and marketed as single (Viread®), double (Truvada®), triple (Atripla®) and quadruple (Complera® and Stribild®) therapies for HIV. Dr. Cundy started his scientific career at Sterling Winthrop, a pharmaceutical division of Eastman Kodak Company, where he led efforts to design and evaluate novel formulation technologies exploiting Kodak’s historical capabilities. He was coinventor of Nanocrystal® technology, a novel formulation approach for poorly soluble drugs that was subsequently used in many approved drug products. Dr. Cundy received a B.S. in pharmacy from the University of Manchester and was registered as a pharmacist in the United Kingdom before earning a Ph.D. in pharmaceutical sciences from the University of Kentucky and postdoctoral training in Biochemistry at the University of California, Berkeley.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Adial Pharmaceuticals (ADIL) CEO Issues Letter to Shareholders
- Hepion Pharmaceuticals (HEPA) Appoints Anand Reddi and Kaouthar Lbiati to its Board
- FreightCar America (RAIL) Appoints Rodger L. Boehm, Jose De Nigris, and Travis D. Kelly to its Board
Create E-mail Alert Related CategoriesCorporate News, Management Changes
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!